One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Measuring Patient Experience in Inflammatory Bowel Disease Care: A Key Component of Continuous Quality Improvement
Subrata Ghosh, Marietta Iacucci
doi : 10.1093/ecco-jcc/jjaa221
Volume 15, Issue 3, March 2021, Pages 347–348
It is important to understand patient experience as we strive to provide patient-centred care in inflammatory bowel disease [IBD]. Patient experience is a composite of all the interactions and interplay between the healthcare system and the patient, which in the case of IBD is often long-term and in multi-dimensional, multi-specialty and multi-settings. Patients highly value getting timely appointments, proper access to information and understanding it, engagement in decisions and good communication. Patient experience, however, is quite distinct from patient satisfaction. Satisfaction depends on whether expectations from the healthcare system have been met1 and this may depend on factors that have set these in...
WE-CARE IBD SCORE: Assessing High-quality Care From the Perspective of Patients With Inflammatory Bowel Disease
Serena Barello, Elena Guida, Andrea Bonanomi, Julia Menichetti, Salvatore Leone ...
doi : 10.1093/ecco-jcc/jjaa174
Volume 15, Issue 3, March 2021, Pages 349–357
Patient-reported experience measures [PREMs] are today a core asset to orientate health care quality improvements. They are particularly relevant in clinical situations requiring frequent interactions between patients and the health care system, like inflammatory bowel disease [IBD]. Indeed, IBD chronic care requires continuous therapies, psychological interventions, and follow-ups. The characteristics of health care services play an important role in the life of these patients and in their satisfaction with the care received. The aim of this study was to develop and validate an IBD-specific questionnaire [WE-CARE IBD SCORE] able to capture IBD patients’ needs and priorities for their own health care and based on patients’ perspectives.
Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016
Katsuyoshi Matsuoka, Ataru Igarashi, Noriko Sato, Yuri Isono, Maki Gouda ...
doi : 10.1093/ecco-jcc/jjaa172
Volume 15, Issue 3, March 2021, Pages 358–366
Recent treatment guidelines for ulcerative colitis [UC] do not recommend long-term corticosteroid [CS] use. The present study aimed to capture the changes in CS use from 2006 to 2016 and to identify factors associated with long-term CS use after 2014, when the first two anti-tumour necrosis factor antibodies [infliximab and adalimumab] became available.
Disease Activity Patterns in the First 5 Years After Diagnosis in Children With Ulcerative Colitis: A Population-Based Study
M Aloi, M Bramuzzo, L Norsa, S Arrigo, M Distante ...
doi : 10.1093/ecco-jcc/jjaa203
Volume 15, Issue 3, March 2021, Pages 367–374
The aim of this study was to define clusters of activity in a population-based cohort during the first 5 years after diagnosis in children with ulcerative colitis [UC] and to identify early prognostic risk factors.
Stage at Diagnosis and Survival of Colorectal Cancer With or Without Underlying Inflammatory Bowel Disease: A Population-based Study
Chanpreet Arhi, Alan Askari, Subramanian Nachiappan, Alex Bottle, Naila Arebi ...
doi : 10.1093/ecco-jcc/jjaa196
Volume 15, Issue 3, March 2021, Pages 375–382
Inflammatory bowel disease [IBD] is a risk factor for colorectal cancer [CRC]. The aim of this study is to determine whether stage at diagnosis and survival differ between sporadic, ulcerative colitis [UC]- and Crohn’s disease [CD]-related CRC.
Impaired Fertility in Women With Inflammatory Bowel Disease: A National Cohort Study From Sweden
Emma Druvefors, Kalle Landerholm, Ulf Hammar, P?r Myrelid, Roland E Andersson
doi : 10.1093/ecco-jcc/jjaa191
Volume 15, Issue 3, March 2021, Pages 383–390
Inflammatory bowel disease [IBD] has been associated with reduced female fertility. We analyse fertility in a national cohort of women with IBD.
Disease Activity Patterns of Crohn’s Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort
Dion Wintjens, Francois Bergey, Edoardo Saccenti, Steven Jeuring, Tim van den Heuvel ...
doi : 10.1093/ecco-jcc/jjaa173
Volume 15, Issue 3, March 2021, Pages 391–400
Real-life data on long-term disease activity in Crohn’s disease [CD] are scarce. Most studies describe disease course by using proxies, such as drug exposure, need for surgery or hospitalisations, and disease progression. We aimed to describe disease course by long-term disease activity and to identify distinctive disease activity patterns in the population-based IBD South Limburg cohort [IBDSL].
Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results From a Territory-wide Hong Kong IBD Registry
Joyce Wing Yan Mak, Carmen Lok Tung Ho, Kylie Wong, Tsz Yan Cheng, Terry Cheuk Fung Yip ...
doi : 10.1093/ecco-jcc/jjaa181
Volume 15, Issue 3, March 2021, Pages 401–408
Elderly-onset inflammatory bowel disease [IBD], defined as age??60 at diagnosis, is increasing worldwide. We aimed to compare clinical characteristics and natural history of elderly-onset IBD patients with those of adult-onset IBD patients.
A Reappraisal of Outcome of Elective Surgery After Successful Non-Operative Management of an Intra-Abdominal Abscess Complicating Ileocolonic Crohn’s Disease: A Subgroup Analysis of a Nationwide Prospective Cohort
M K Collard, S Benoist, L Maggiori, P Zerbib, J H Lefevre ...
doi : 10.1093/ecco-jcc/jjaa217
Volume 15, Issue 3, March 2021, Pages 409–418
Few prospective data exist on outcomes of surgery in Crohn’s disease [CD] complicated by an intra-abdominal abscess after resolution of this abscess by antibiotics optionally combined with drainage.
Diagnostic Delay Is Associated With Complicated Disease and Growth Impairment in Paediatric Crohn’s Disease
Amanda Ricciuto, David R Mack, Hien Q Huynh, Kevan Jacobson, Anthony R Otley ...
doi : 10.1093/ecco-jcc/jjaa197
Volume 15, Issue 3, March 2021, Pages 419–431
Paediatric data on the association between diagnostic delay and inflammatory bowel disease [IBD] complications are lacking. We aimed to determine the effect of diagnostic delay on stricturing/fistulising complications, surgery, and growth impairment in a large paediatric cohort, and to identify predictors of diagnostic delay.
Impact of an Education Programme on IBD Patients’ Skills: Results of a Randomised Controlled Multicentre Study [ECIPE]
J Moreau, N Hammoudi, L Marthey, C Trang-Poisson, M Nachury ...
doi : 10.1093/ecco-jcc/jjaa195
Volume 15, Issue 3, March 2021, Pages 432–440
Better patient knowledge on inflammatory bowel disease [IBD] could improve outcome and quality of life. The aim of this study was to assess if an education programme improves IBD patients’ skills as regards their disease.
Dissecting Common and Unique Effects of Anti-?4?7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis
Marisol Veny, Alba Garrido-Trigo, Ana M Corraliza, Maria C Masamunt, Helena Bassolas-Molina ...
doi : 10.1093/ecco-jcc/jjaa178
Volume 15, Issue 3, March 2021, Pages 441–452
Vedolizumab is an anti-?4?7 antibody approved for the treatment of ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the unique mechanisms of action of vedolizumab in UC patients, we compared its effects to those induced by anti-tumour necrosis factor [TNF].
Re-Evaluating the Evidence for Faecal Microbiota Transplantation ‘Super-Donors’ in Inflammatory Bowel Disease
Scott W Olesen, Ylaine Gerardin
doi : 10.1093/ecco-jcc/jjaa170
Volume 15, Issue 3, March 2021, Pages 453–461
Faecal microbiota transplantation [FMT] is a recommended treatment for recurrent Clostridioides difficile infection, and there is promise that FMT may be effective for conditions such as inflammatory bowel disease [IBD]. Previous FMT clinical trials have considered the possibility of a ‘donor effect’, that is, that FMT material from different donors has different clinical efficacies.
Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn’s Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials
Neeraj Narula, Emily C L Wong, Parambir S Dulai, John K Marshall, Jean-Frederic Colombel ...
doi : 10.1093/ecco-jcc/jjaa189
Volume 15, Issue 3, March 2021, Pages 462–470
There is need for biomarkers as predictors of outcome of medical treatment in Crohn’s disease. The purpose of this study was to evaluate the predictive performance of faecal calprotectin for short- and long-term clinical and endoscopic outcomes.
The JAK Inhibitor Tofacitinib Rescues Intestinal Barrier Defects Caused by Disrupted Epithelial-macrophage Interactions
Marianne R Spalinger, Anica Sayoc-Becerra, Christ Ordookhanian, Vinicius Canale, Alina N Santos ...
doi : 10.1093/ecco-jcc/jjaa182
Volume 15, Issue 3, March 2021, Pages 471–484
Loss-of-function variants in protein tyrosine phosphatase non-receptor type-2 [PTPN2] promote susceptibility to inflammatory bowel diseases [IBD]. PTPN2 regulates Janus-kinase [JAK] and signal transducer and activator of transcription [STAT] signalling, while protecting the intestinal epithelium from inflammation-induced barrier disruption. The pan-JAK inhibitor tofacitinib is approved to treat ulcerative colitis, but its effects on intestinal epithelial cell-macrophage interactions and on barrier properties are unknown. We aimed to determine if tofacitinib can rescue disrupted epithelial-macrophage interaction and barrier function upon loss of PTPN2.
Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon
Bram Verstockt, Sare Verstockt, Saeed Abdu Rahiman, Bo-jun Ke, Kaline Arnauts ...
doi : 10.1093/ecco-jcc/jjaa185
Volume 15, Issue 3, March 2021, Pages 485–498
Patients with inflammatory bowel disease [IBD] are considered immunosuppressed, but do not seem more vulnerable for COVID-19. Nevertheless, intestinal inflammation has shown to be an important risk factor for SARS-CoV-2 infection and prognosis. Therefore, we investigated the role of intestinal inflammation on the viral intestinal entry mechanisms, including ACE2, in IBD.
Extracellular Vesicles in Inflammatory Bowel Disease: Small Particles, Big Players
M Valter, S Verstockt, J A Finalet Ferreiro, I Cleynen
doi : 10.1093/ecco-jcc/jjaa179
Volume 15, Issue 3, March 2021, Pages 499–510
Extracellular vesicles are nanovesicles released by many cell types into the extracellular space. They are important mediators of intercellular communication, enabling the functional transfer of molecules from one cell to another. Moreover, their molecular composition reflects the physiological status of the producing cell and tissue.
Ten Reasons to Think About Bile Acids in Managing Inflammatory Bowel Disease
Michael Camilleri
doi : 10.1093/ecco-jcc/jjaa175
Volume 15, Issue 3, March 2021, Pages 511–515
There are ten good reasons why it is important to think about abnormalities in bile acid control in inflammatory bowel disease. Before reviewing these reasons, it is relevant to review essential elements in the enterohepatic circulation, synthesis and actions of bile acids.
Corrigendum to: DOP01 Exclusive Enteral Nutrition for the Treatment of Adult Crohn’s Disease
D Shukla, L Purcell, M Palmer, L Pillay
doi : 10.1093/ecco-jcc/jjaa169
Volume 15, Issue 3, March 2021, Page 516
Corrigendum to: Diagnostic Yield of Next-Generation Sequencing in Very Early-Onset Inflammatory Bowel Diseases: A Multicenter Study
Fabienne Charbit-Henrion, Marianna Parlato, Sylvain Hanein, Rémi Duclaux-Loras, Jan Nowak ...
doi : 10.1093/ecco-jcc/jjaa164
Volume 15, Issue 3, March 2021, Pages 517–518
